Abbott’s Panbio Rapid Antigen Test Receives CE Mark for Mass COVID-19 Screening
Shots: AbCellera to receive technology access fee, milestones and royalties on the development and commercialization of pre-cliniocal candidates & will develop Abs for Denali’s eight targets for neurological disorders On 12 Jun,2018 Denali therapeutics collaborated with AbCellera for its single-cell technology to develop hundreds of mAbs for neurodegenerative diseases AbCellera’s single-cell screening technology is a […]Read More
